4.5 Article

The global roadmap for advancing development of vaccines against sexually transmitted infections: Update and next steps

Journal

VACCINE
Volume 34, Issue 26, Pages 2939-2947

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2016.03.111

Keywords

Sexually transmitted infections; Vaccines; STI vaccine development; Roadmap

Funding

  1. Agenus
  2. Genocea
  3. Vical
  4. Gilead
  5. AiCuris
  6. Sanofi

Ask authors/readers for more resources

In 2014, the World Health Organization, the US National Institutes of Health, and global technical partners published a comprehensive roadmap for development of new vaccines against sexually transmitted infections (STIs). Since its publication, progress has been made in several roadmap activities: obtaining better epidemiologic data to establish the public health rationale for STI vaccines, modeling the theoretical impact of future vaccines, advancing basic science research, defining preferred product characteristics for first-generation vaccines, and encouraging investment in STI vaccine development. This article reviews these overarching roadmap activities, provides updates on research and development of individual vaccines against herpes simplex virus, Chlamydia trachomatis, Neisseria gonorrhoeae, and Treponema pallidum, and discusses important next steps to advance the global roadmap for STI vaccine development. (C) 2016 World Health Organization; licensee Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.orgilicensesiby/3.0/).

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available